Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) has received a consensus rating of “Hold” from the nine analysts that are currently covering the stock, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $10.29.
Several research firms have issued reports on RVNC. HC Wainwright lowered shares of Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 13th. Stifel Nicolaus cut their price objective on shares of Revance Therapeutics from $24.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Barclays restated an “equal weight” rating and issued a $7.00 price objective (down from $10.00) on shares of Revance Therapeutics in a research note on Friday, September 13th. William Blair reiterated a “market perform” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Finally, Guggenheim restated a “neutral” rating on shares of Revance Therapeutics in a research note on Monday, August 12th.
Check Out Our Latest Report on RVNC
Hedge Funds Weigh In On Revance Therapeutics
Revance Therapeutics Price Performance
Shares of NASDAQ RVNC opened at $5.30 on Friday. Revance Therapeutics has a 1-year low of $2.30 and a 1-year high of $9.74. The business has a fifty day moving average price of $5.89 and a 200 day moving average price of $4.30. The stock has a market capitalization of $555.55 million, a P/E ratio of -1.66 and a beta of 0.98.
Revance Therapeutics (NASDAQ:RVNC – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.12. The firm had revenue of $65.39 million during the quarter, compared to the consensus estimate of $66.30 million. During the same quarter in the prior year, the business posted ($0.80) earnings per share. The firm’s quarterly revenue was up 20.2% on a year-over-year basis. As a group, equities research analysts anticipate that Revance Therapeutics will post -1.53 earnings per share for the current fiscal year.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
Read More
- Five stocks we like better than Revance Therapeutics
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- What Makes a Stock a Good Dividend Stock?
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- What Are Dividend Contenders? Investing in Dividend Contenders
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.